Caredx reports second quarter 2023 results

Brisbane, calif.--(business wire)--caredx, inc. (nasdaq: cdna) – the transplant company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today reported financial results for the second quarter ended june 30, 2023. second quarter 2023 highlights and other recent updates caredx received the industry's first and only multimodal moldx approval in transplant with heartcare for medicare.
CDNA Ratings Summary
CDNA Quant Ranking